WO2008040187A1 - Application of astilbin in preparation of medicament for treating or preventing acute or chronic renal failure, kidney fibrosis and diabetic renopathy - Google Patents

Abstract

Use of astilbin in preparation of medicament for treating or preventing acute or chronic renal failure, kidney fibrosis and diabetic renopathy and its pharmaceutical composition, which provides the possibility obtaining the new medicament for treating multiple renal diseases.

Description

 Application of astilbin in the preparation of medicine for treating or preventing acute and chronic renal failure, renal fibrosis and diabetic nephropathy

Technical field:

 The present invention relates to the use of astilbin in the manufacture of a medicament for the treatment or prevention of acute and chronic renal failure and renal fibrosis. Background technique:

 Astilbin has anti-myocardial ischemia, immune regulation, anti-inflammatory, analgesic and other pharmacological effects [Shao Chunhong, Xinhua, Zhou Chengming et al. Protective effect of saponin on myocardial ischemia in rats. Journal of Xinjiang Medical University, 2000, 23 ( 3): 205-207.; Gao Sihai, Pan Tiecheng. Extraction of astilbin and its protective effect on myocardial ischemia-reperfusion injury. Chinese Journal of Practical Traditional Chinese and Western Medicine, 2003, 3: 1693-1694]. The present inventors have invented the application of astilbin in the preparation of a medicament for treating or preventing acute and chronic renal failure, renal fibrosis and diabetic nephropathy through a large number of experimental studies. Summary of the invention:

 The present invention provides the use of astilbin in the preparation of a medicament for treating or preventing acute and chronic renal failure, renal fibrosis and diabetic nephropathy.

 The present invention provides the use of astilbin in the preparation of a medicament for treating or preventing acute renal failure. The present invention provides the use of astilbin in the preparation of a medicament for treating or preventing chronic renal failure. The present invention provides the use of astilbin in the preparation of a medicament for treating or preventing renal fibrosis.

 The present invention provides the use of astilbin in the preparation of a medicament for treating or preventing diabetic nephropathy.

 The present invention provides a pharmaceutical composition for acute and chronic renal failure, renal fibrosis, and diabetic nephropathy using astilbin as an active ingredient.

 The aspirin provided by the present invention is used for the acute and chronic renal failure, renal fibrosis and diabetic nephropathy, and the dosage range thereof is 10 mg~: 1000 mg/day/person; preferably 10~500 mg/day/ For humans, the dosage range for oral administration is 10 mg~; 1000 mg/day/person; preferably 10 to 500 mg/day/person.

The astilbin may be prepared according to the literature (Li Yuqi, Li Yulian, Zhang Kejin et al. Separation and structural identification of saponin. Chinese Journal of Pharmaceutical Sciences, 1999, 15 (1): 42-44.), preferably according to the method disclosed. Prepared by the following method: After pulverizing the sputum medicinal material, add 80% ethanol solution to soak overnight; extract 2 times, each time 10 times volume, combine the concentrated solution and de-alcohol to 5 times volume, then use water N2007/002818 Dilute to 20 times volume, place the precipitate; Filter the supernatant onto the polyamide column, first elute 6 column volumes with water, then elute with 8% alcohol solution to '8 column volume, collect The eluate is concentrated until a precipitate is precipitated; the precipitate is taken by filtration, dried to obtain crude astilbin, and recrystallized.

 The astilbinin pharmaceutical composition provided by the present invention may be added in the form of an injection, a tablet, a pill, a granule, a capsule, a syrup or the like according to the needs of the preparation, and is preferably a lyophilized powder needle and a capsule. The various dosage forms provided by the present invention can be prepared by a conventional method of pharmacy.

 The present inventors conducted the following tests to confirm the use of astilbin for the treatment or prevention of acute and chronic renal failure, renal fibrosis and diabetic nephropathy, but the pharmacological action is not limited thereto.

BRIEF DESCRIPTION OF THE DRAWINGS:

 Figure 1 shows a pathological section (H&E staining) of the effect of astragaloside on adenine-induced chronic renal failure in rats.

 Figure 2 shows a pathological section (Masson staining) of the effect of astragaloside on adenine-induced chronic renal failure in rats. detailed description:

Preparation Example 1: Preparation of astilbin

Take 5kg of scorpion medicinal material, smash and add 60% ethanol solution to soak overnight; extract 2 times, first 60L, second 40L, combine the extract and concentrate to dealcohol to 5L, then dilute to 20L with water, place Precipitation; filter the supernatant on a polyamide column (CV = 5L), first elute 6 column volumes with acid water (pH = 2), then elute 8 column volumes with 20% alcohol solution, collect The eluate was concentrated to precipitate a precipitate; the precipitate was filtered and dried to give crude astilbin 42g, astilbin recrystallized to give pure 34 _g, purity 95.8%.

Preparation 2: Preparation of astilbin

 Take 5kg of scorpion medicinal material, pulverize and infiltrate with 20 times of 80% ethanol solution; combine osmotic solution, concentrate to dealcohol to 3L, dilute with water to 15L, place sediment; filter to take supernatant on AB-8 Porous resin chromatography column (CV=5L), first elute 4 column volumes with water, then elute 4 column volumes with 10% alcohol solution, and finally elute 12 column volumes with 20% alcohol solution, collect 20 The % alcohol solution was deliquored and concentrated to precipitate out; the precipitate was collected by filtration, dried to obtain 38 g of crude astilbin, and recrystallized to obtain 28 g of astilbin. Purity 97.8%.

Preparation 3 Preparation of astilbin tablet

Weighing 10. 0 g of astilbin, 115. 0 g of powdered sugar, 40.0 g of lactose and 23.0 g of sodium carboxymethyl starch were mixed well and passed through a 100 mesh sieve, and an appropriate amount of 3% PVP _{K3 was added} . The right amount of the soft material is made into a soft material, 20 mesh sieve granules, 60 Ό dry for 3 hours, 18 mesh sieve granules, added 2.0 g of magnesium stearate, and uniformly mixed, and then pressed 1000 tablets. Each piece weighs about 200mg, which is obtained.

Preparation 4 Preparation of astilbin soft capsule

 Weigh 10.0 g of astilbin and 200 ml of medicinal soybean oil, mix well, add 10 g of paraffin, 10 g of polysorbate 80, and make 1000 soft capsules, each weighing about 250 mg.

Preparation 5 Preparation of astilbinin dropping pills

 Take 30mg of polyethylene glycol 4000 and 10.0g of astilbin, respectively, and then heat and melt in a constant temperature water bath at 75 °C, stir for 75 hours under stirring for 1 hour to make the dispersion uniform, and transfer the liquid to the dropping machine at 75 °C. In the storage tank, the diameter of the dripper is 5. 0/6. 0mm, the dropping speed is 60 drops/min, the coolant is dimethyl silicone oil, and the temperature of the cooling liquid is 10 Ό, the weight of the dropping pills is 60 mg, and the dropping is made. 1000 pills, remove the cooling liquid on the surface of the dropping pills, that is.

Preparation Example 6 Preparation of astilbin injection

 Astilbin 10.0 g, add water for injection to 1000 ml 60 ° C to dissolve, and then filter the microporous membrane to make 1000 injections.

Test 1 Effect of astilbin on acute renal failure in rats

 1. 1 drugs and reagents

 Astilbin is prepared according to Preparation Example 1, Preparation Example 3, Preparation Example 6;

 Jia Qianglong (Belgium Pharmacia, Belgium specification: 300mg/branch, batch number: 040706), is a positive control drug;

 Creatinine and Urea Nitrogen Kit (Beijing Zhongsheng Technology Co., Ltd., batch number: 050606), as a test kit; Experimental animals: SPF Sprague Dawley rats, weighing 150 g-200 g, provided by Shandong Luye Pharmaceutical Co., Ltd. Experimental Animal Center The animal certificate number is: SYXK (Lu) 20030020.

 1. 2 Test methods and results

Rats were randomly divided into normal group, model group, methylprednisolone (12 mg/kg) group, astilbin IV 1 mg/kg group, and astilbin IV 5 rag/kg group. Intravenous injection of 25 mg/kg of genistein, 50 mg/kg of astilbin, 50 mg/kg of astilbin, 100 mg/kg of astilbin, 1 mg/kg of astilbin, 5 mg of astilbin /kg group, astilbin gavage 25 mg / kg group, astilbin gavage 50 mg / kg group, astilbin gavage 100 mg / kg group, 10 per group. The normal group and the model group were administered with normal saline by gavage, and the other administration groups were administered by intragastric administration or intravenous administration according to the dosage and manner of administration. Each group was administered continuously for 2 days. The glycerol solution was formulated into 50% (V/V). Except the normal group, the rats in each group were banned from water. After 16 hours, the glycerol solution was intramuscularly injected with 1 mL/100 g, and then each group was administered once again. Normal group and model group The same volume of physiological saline was administered, and blood was taken from the eyes of the experimental animals 24 hours later, and creatinine and urea nitrogen were measured according to the creatinine and urea nitrogen kits, respectively. Data were expressed as gentleman SD and T-test was performed between groups. The measurement results are shown in Table 1. Table 1 Effect of astilbin on serum creatinine and urea nitrogen in rats with acute renal failure (* soil SD, n=10)

 *, P<0. 05, ", Ρ<0· 01, compared with the model group

The results showed that astragaloside intravenous injection of 1 mg / kg ~ 100 mg / kg, astilbin gavage 1 mg / kg ~ 100 mg / kg significantly reduced serum creatinine and urea nitrogen levels in rats with acute renal failure (compared with the model group) , P<0.05 or P<0.01) ₀

Test 2 Effect of astilbin on chronic renal failure in rats induced by adenine

 2. 1 Drugs and reagents

 Astilbin is prepared according to Preparation Example 1, Preparation Example 4 and Preparation Example 6;

 Adenine (Changzhou Huatong Chemical Company)

Glutathione (Shandong Green Leaf Pharmaceutical Co., Ltd., Specification: 300mg/piece, batch number: 040706), for Positive control drug;

 Creatinine and Urea Nitrogen Kit (Beijing Zhongsheng Technology Co., Ltd., batch number: 050606), as a test kit; Experimental animals: SPF Sprague Dawley rats, weighing 150 g-200 g, provided by Shandong Luye Pharmaceutical Co., Ltd. Experimental Animal Center The animal certificate number is: SYXK (Lu) 20030020.

 2. 2 Test methods and results

 One week after adaptive feeding in rats, the animals were intraperitoneally injected with adenine 150rag/kg for 7 consecutive days except for the normal group. After 24 hours, the rats were bled in the eye, and serum creatinine and urea nitrogen were measured. Body weight, serum creatinine and urea. Nitrogen grouping. Animals were divided into normal group, model group, glutathione intravenous injection (150 mg/kg) group, astilbin intravenous injection 1 mg/kg group, astilbin intravenous injection 5 mg/kg group, astilbin intravenous injection In the 25 mg/kg group, 50 mg/kg of astilbin was given intravenously, 100 mg/kg of astilbin, 100 mg/kg of astilbin, 1 mg/kg of astilbin, and 5 mg/kg of astilbin. After administration of astilbin in the 25 mg/kg group, astilbin was intragastrically administered in the 50 mg/kg group, and astilbin was administered to the 100 mg/kg group, with 10 rats in each group. The administration was started after the 8th day of modeling, and the normal group and the model group were administered with normal saline by gavage, and the other administration groups were administered by intragastric administration or intravenous administration according to the dosage and manner of administration. Blood was taken from the eyelids after 14 days of continuous administration. Serum creatinine and urea nitrogen (creatinine and urea nitrogen kit were used to measure creatinine and urea nitrogen), and the experimental animals were sacrificed for pathological section. H&E staining and Masson staining were used to observe the pathological changes of renal tissue. The degree of fibrosis. The data is indicated by the SD, and the T-test is performed between the groups. See Table 2 for the results of the measurements.

 Table 2 Effect of astilbin on serum creatinine and urea nitrogen in rats with chronic renal failure (Soil SD, n=10)

 Group dose (mg kg) serum creatinine serum urea nitrogen (mg/dL)

 (mg dL) normal group - 0.49 ± 0.07 9. 85 ± 2.55 model group -- 2.04 ± 0.22 40.53 ± 4.51 glutathione group 150 1.15 ± 0.13" 18.21 ± 3.25**

 1 1.80±0.18* 35.91±3.60* astilbin injection group 5 1.52±0.37** 30.42±7.36"

 25 1.32±0.28" 26.76±4.19**

 50 1.20±0.22** 22.07±3.45**

100 1.19±0.39** 21.85±5.88** 1 1.82±0.19* 36.37±3.85"

 Astilbin gavage group 5 1.67±0.28** 31.47±5.60"

 25 1.55±0.28** 28.46±3.95**

 50 1.54±0.26" 27.86±5.30**

 100 1.50±0.22" 26.8 5.20"

', P<0. 05, ^w , P<0. 01, compared with the model group

 The results showed that astragaloside intravenous injection of 1 mg / kg ~ 100 mg / kg, astilbin gavage 1 mg / kg ~ 100 mg / kg significantly reduced serum creatinine and urea nitrogen levels in rats with chronic renal failure caused by adenine (Compared with the model group, P<0.05 or P<0.01).

 Pathological examination results: As shown in Figure 1 and Figure 2, the normal group of renal tissue cells are normal and closely arranged; the model group has obvious renal tissue crystal precipitates, renal tubular destruction, atrophy, and small lumen, which shows lymphocytic infiltration And local fibrous tissue hyperplasia, glomerular enlargement, vacuolar degeneration of glomerular epithelial cells, a large amount of loose material under the endothelial cells, thickening of the basement membrane. Each dose of astilbin (administered in the 25 mg/kg group) can significantly reduce renal tissue damage and fibrous tissue formation.

Test 3 Effect of astilbin on renal failure in rats with renal failure

 3. 1 drugs and reagents

 Astilbin is prepared according to Preparation Example 2, Preparation Example 5, Preparation Example 6;

 Glutathione (Shandong Green Leaf Pharmaceutical Co., Ltd., Specification: 300mg/branch, batch number: 040706), is a positive control drug;

 Creatinine and Urea Nitrogen Kit (Beijing Zhongsheng Technology Co., Ltd., batch number: 050606), as a test kit; Experimental animals: SPF Sprague Dawley rats, weighing 150 g-200 g, provided by Shandong Luye Pharmaceutical Co., Ltd. Experimental Animal Center The animal certificate number is: SYXK (Lu) 20030020.

 3. 2 Test methods and results

 One week after adaptive feeding in rats, the animals were anesthetized with chloral hydrate (350 mg/kg, ip) except the normal group (20 rats), and a 5/6 nephrectomy method was used to make a chronic renal failure model [Gretz N, Waldherr R,

Karger, Basel 1993 pp: 1- 28.], the first surgery to remove the left kidney 2 / 3, a week after the second surgery to remove the right kidney. Five weeks after the second operation, blood was taken from the rat's eye frame, and serum creatinine and urea nitrogen were measured. The animals were divided into 12 groups according to body weight, serum creatinine and urea nitrogen. Each group was 20, that is, the model group, glutathione. Intravenous injection of glycoside (150mg/kg), intravenous injection of astilbin in the 1 mg/kg group, intravenous injection of astilbin In the 5 mg/kg group, the 4 mg/kg group of astilbin was given intravenously, the 50 mg/kg group of astilbin was given intravenously, the 100 mg/kg group of astilbin was given intravenously, and the img/kg group was administered with astilbin. After administration of astilbin in the 5 mg/kg group, astilbin was intragastrically administered in the 25 mg/kg group, astilbin was administered to the 50 mg/kg group, and astilbin was administered to the 100 mg/kg group. The normal group and the model group were administered with normal saline by gavage, and the other administration groups were administered by intragastric administration or intravenous administration according to the dosage and manner of administration. Rats were continuously administered for 4 weeks and 8 weeks, and blood was taken from the ocular frame. Serum creatinine and urea nitrogen were measured. Ten experimental animals were sacrificed in each group for 4 weeks. The remaining experimental animals were sacrificed at the end of the 8 weeks of the experiment. , H&E staining, Masson staining to observe the pathological changes of renal tissue and the degree of fibrosis. Observe the pathological changes of kidney tissue. Data were expressed in terms of SD and T-test was performed between groups. See Table 3 and Table 4 for the test results.

 Table 3 Effect of astilbin on serum creatinine and urea nitrogen in rats with chronic renal failure after nephrectomy for 4 weeks

 (X±SD, n=20)

*, Ρ<0. 05, **, Ρ<0. 01, compared with the model group Table 4 Effect of astilbin on serum creatinine and urea nitrogen in rats with chronic renal failure after renal resection for 8 weeks

 (X +SO, n=20)

 ', P<0. 05, ", P<0.01, compared with the model group

 The results are shown in Table 3 and Table 4. Intravenous injection of 1 mg/kg to 100 mg/kg of astilbin and 1 mg/kg to 100 mg/kg of astilbin in the treatment significantly reduced the chronic renal failure caused by adenine. Serum creatinine and urea nitrogen levels (compared with the model group, P < 0.05 or P < 0.01) o

The results of pathological examination showed that the glomeruli had different degrees of compensatory hypertrophy, mesangial cell proliferation, mesangial matrix increased, glomerular capillary loops were lobulated, part of the kidneys under the light microscope of the 8th week of administration. The small balloon cavity disappears, the capillary wall thickens, the renal tubules swell and expand, the protein is deposited in the lumen, some of the tubules are atrophied, the interstitial inflammatory cells infiltrate, and the fibrous tissue proliferate. The above changes were also observed in the administration groups of astilbin. However, the degree of lesions is mild, and the degree of lesions decreases with increasing dose.

Experiment 4 Effect of astilbin on renal interstitial fibrosis in rats with unilateral ureteral ligation

 4. 1 Materials

 Astilbin is prepared according to Preparation Example 2 and Preparation Example 3, Preparation Example 6;

 Experimental animals: SPF grade Sprague Dawley rats, weighing 220 g-250 g, provided by Shandong Luye Pharmaceutical Co., Ltd. Experimental Animal Center, animal certification number: SYXK (Lu) 20030020.

 Luo Tingxin, produced by Beijing Novartis Pharmaceutical Co., Ltd., batch number: 040306; positive control drug group; hydroxyproline kit, Nanjing Jianfei Biological Company, batch number: 050906, as test kit.

 4. 2 Test methods and results

 One week after adaptive feeding in rats, chloral hydrate (350 rag/kg, ip) was anesthetized, and the right lateral position of the rat was fixed on the operating table. After shearing, the operation area was disinfected with iodine and 75% alcohol. The flank incision was made to cut the skin, muscle and abdominal wall layer by layer. The left ureter was exposed and separated, 4-0 silk ligature was ligated and the ureter was blocked, sutured layer by layer, and penicillin was intramuscularly injected. Rats in the sham operation group (10 rats) underwent only left ureteral separation surgery. Rats with successful model were randomly divided into 12 groups: model group, Luotingxin (4 mg/kg) group, astilbin IV 1 mg/kg group, and astilbin IV 5 mg/kg group. Intravenous injection of 25 mg/kg of astilbin, 50 rag/kg group of astilbin, 50 mg/kg of astilbin, 100 mg/kg of astilbin, 1 mg/kg of astilbin, 5 g of genistein In the mg/kg group, astilbin was intragastrically administered in the 25 mg/kg group, astilbin was administered intragastrically in the 50 mg/kg group, and astilbin was administered intragastrically in the 100 mg/kg group, with 10 rats in each group. The pseudo-surgical group and the model group were administered with normal saline by gavage, and the other administration groups were administered orally or intravenously according to the dosage and manner of administration. After 21 days of continuous administration, each group of animals was sacrificed after anesthesia with 10% chloral hydrate. The left kidney was left after repeated lavage with saline, and the kidney tissue was fixed with 4% paraformaldehyde buffer. An appropriate amount of kidney tissue was excised, and hydroxyproline was determined according to the hydroxyproline kit assay. Data were expressed as soil SD and T-test was performed between groups. The test results are shown in Table 5.

 Table 5 Effect of astilbin on renal hydroxyproline content in rats with unilateral ureteral obstruction Soil SD, n=10)

 Group dose (mg/kg) hydroxyproline (g/g) sham operation group ― 305±56 model group -- 760±156 Luo Ting new group 4 487±132

 1 612±118*

 Astilbin injection group

5 550±87*' 25 533±94**

 50 526±121**

 100 705±161

 1 610±115*

 Astilbin gavage group

 5 540±87"

 25 523±94"

 50 518±12l"

 100 511±10l"

 P<0.05, **, P<0.01, compared with the model group

 The results are shown in Table 5. Intravenous injection of 1 mg/kg to 100 mg/kg of astilbin, 1 mg/kg to 100 mg/kg of astilbin, significantly reduced the renal fibrosis induced by unilateral ureter. Renal tissue hydroxyproline levels (P<0.05 or P<0.01) compared with the model group.

Test 5 Effect of astilbin on rats with diabetic nephropathy

 5. 1 Materials

 Astilbin is prepared according to Preparation Example 1, Preparation Example 4, Preparation Example 6;

 Benazepril, produced by Beijing Novartis Pharmaceutical Co., Ltd., batch number: 040306; positive control drug; streptozotocin (Sigma), for diabetes model

 Blood glucose determination kit (Beijing Zhongsheng Reagent Co., Ltd. batch number: 060503); creatinine and urea nitrogen test kit (Beijing Zhongsheng Technology Co., Ltd., batch number: 060606); as test kit;

 Experimental animals: SPF grade Sprague Dawley rats, weighing 220 g-250 g, provided by Shandong Luye Pharmaceutical Co., Ltd. Experimental Animal Center, animal certification number: SYXK (Lu) 20030020.

 5. 2 Test methods and results

One week after adaptive feeding in rats, the animals were anesthetized with chloral hydrate (350 mg/kg, ip) except for the normal group (10 rats). Left kidney enucleation was performed, and a single intravenous injection of 1% streptozoon was given one week later.素素素素素, streptozotocin, 0. 1 mol / L, pH of 4.5 citrate buffer solution, 72 h after eyelid blood collection, blood glucose determination kit, blood glucose 16. 7 Mmmol/L was determined to be successful in modeling. After 4 weeks, according to blood glucose, body weight, urine volume and urine protein group, they were randomly divided into 12 groups, namely model group, benazepril (2 mg/kg) group, astilbin, 1 mg/kg group, astilbin. Intravenous injection of 5 mg/kg group, astilbin intravenous injection of 25 mg/kg group, astilbin intravenous injection of 50 rag/kg group, astilbin intravenous injection of 100 mg/kg group, Astilbin gavage 1 mg/kg group, astilbin gavage 5 mg/kg group, astilbin gavage 25 mg/kg group, astilbin gavage 50 m _g / kg group, astilbin gavage 100 mg /kg group, 10 per group. The normal group and the model group were administered with normal saline by gavage, and the other administration groups were administered by intragastric administration or intravenous administration according to the dosage and manner of administration. After continuous administration for 4 weeks, blood creatinine and urea nitrogen were measured by eyelid blood sampling and 24h urine protein excretion in each group. After 4 weeks of continuous administration, blood was taken, and serum creatinine and urea nitrogen were measured. The urinary protein excretion of the rats in each group was measured for 24 hours. The pathological changes and fibrosis of renal tissues were observed by H&E staining of the kidney. Perform a pathological examination. The data is represented by bauxite SD and T-test is performed between groups. The test results are shown in Tables 6 and 7.

 Table 6 Effect of astilbin administration for 4 weeks on rats with diabetic nephropathy (±SD, n=10)

*, P<0. 05, **, P<0.01, compared with the model group Table 7 Effect of astilbin administration for 8 weeks on diabetic nephropathy rats (X±SO,

 *, P<0. 05, ", P<0.01, compared with the model group

 The results of blood biochemical indicators are shown in Table 6 and Table 7. Intravenous injection of 1 mg/kg to 100 mg/kg of astilbin and 4 mg/kg to 100 rag/kg of astilbin in 4 weeks and 8 weeks. After the reduction of serum creatinine and urea nitrogen and 24h urinary protein excretion in rats with diabetic nephropathy (P<0.05 or P<0.01).

Pathological examination revealed that the glomerular basement membrane was normal in the normal control group, no widening was observed, and the foot processes were arranged neatly. In the model control group, the glomerular basement membrane was significantly broadened, the foot processes were disordered, fused, and the mesangial cells and the matrix were mildly segmental hyperplasia. The administration group of astilbin was lighter than the model group, and the dose was increased. The pathology is gradually reduced.

Industrial applicability:

 The invention proves that the asparagusin has a pharmacologically significant effect in treating or preventing acute and chronic renal failure, renal fibrosis and diabetic nephropathy through a large number of experiments, and provides a possibility for obtaining a new drug for treating various kidney diseases, suitable for Industrial applications.

Claims

Rights request 1. The use of astilbin in the preparation of a medicament for treating or preventing multiple kidney diseases.  2. The use according to claim 1, wherein the kidney disease is acute renal failure.  3. The use according to claim 1, wherein the kidney disease is chronic renal failure.  4. The use according to claim 1, wherein the kidney disease is renal fibrosis.  5. The use according to claim 1, wherein the kidney disease is diabetic nephropathy.  6. The use according to Claim 1, for the preparation of a pharmaceutical composition for acute and chronic renal failure, renal fibrosis and diabetic nephropathy using astilbin as an active ingredient.  7. The use according to claim 6, wherein the pharmaceutical composition is a lyophilized powder, a tablet, a granule, a capsule, a syrup, a dropping pill or an injection. 8. The tablet according to claim 7, wherein the tablet is prepared by the following method: 10.0 parts by weight of astilbin, 15.0 parts by weight of glucose powder, 40.0 parts by weight of lactose and 23.0 parts by weight of carboxylate The methyl starch sodium was thoroughly mixed and passed through a 100 mesh sieve, and 3% PVP _{K3 was} added. Appropriate amount of soft material in water solution, 20 mesh sieve granules, 60 Ό dry for 3 hours, 18 mesh sieve granules, add 2.0 parts by weight of magnesium stearate, and mix well, then weigh 200 mg per tablet.  9. The use according to claim 7, wherein the soft capsule is prepared in the following manner: 10. 0 parts by weight of astilbin and 200 parts by volume of medicinal soybean oil are thoroughly mixed, and then 10 parts by weight of paraffin and 10 parts by weight are added. The sorbitol ester 80 is obtained by making a soft capsule of 250 mg per weight.  10. The application according to claim 7, wherein the dropping pills are prepared by the following methods: polyethylene glycol 4000 and astilbin, mixed and heated in a 75 ° C constant temperature water bath, and stirred at 75 ° C for 1 Hour the dispersion evenly, the liquid is transferred to a 75 ° C constant temperature storage tank of the dropping machine, the diameter of the dripper is 5. 0/6. 0mm, the dropping speed is 60 drops / minute, the coolant is dimethicone, cooling Liquid temperature 1 (Under TC conditions, adjust the weight of the dropping pills to 60 mg, and make 1000 pills into drops, and remove the cooling liquid on the surface of the dropping pills.  The application according to claim 7, wherein the injection solution is prepared by the following method: astaxanthin 10.0 weight unit, adding water for injection to 1000 volume unit at 60 ° C for heat preservation, and then filtering the microporous membrane. Packed into an injection.